Use of SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors in Pulmonary Hypertension
Inhibiting SGLT2 (sodium-glucose cotransporter 2) has recently transformed the medical care of patients with left heart disease. Right ventricular failure is a major predictor for patients suffering from pulmonary hypertension of various causes, including those with postcapillary pulmonary hypertension due to left heart disease. Similar to how SGLT2 inhibition benefits patients with left heart failure, recent studies have suggested utilizing these molecules to enhance right ventricular function in pulmonary hypertension. In this review, we summarize the current knowledge on the use of SGLT2is (SGLT2 inhibitors) in pulmonary hypertension. Further dedicated trials are necessary to establish their role in right ventricular pulmonary vascular disease.
Authors
- Fabrice Bauer (ORCID: https://orcid.org/0000-0002-9221-9688)
- Marianne Riou (ORCID: https://orcid.org/0000-0001-6807-8582)
- Benoit Aguado (ORCID: https://orcid.org/0009-0005-6895-194X)
- Fabrice Antigny (ORCID: https://orcid.org/0000-0002-9515-6571)
- Grégoire Ruffenach (ORCID: https://orcid.org/0000-0001-6419-4332)
- Thomas Lacoste-Palasset (ORCID: https://orcid.org/0000-0003-3543-6675)
- Valérie B. Schini‐Kerth (ORCID: https://orcid.org/0000-0001-9997-9287)
- David Montani (ORCID: https://orcid.org/0000-0002-9358-6922)
- Marc Humbert (ORCID: https://orcid.org/0000-0003-0703-2892)
- Agnes Görlach
- Mathieu Gourmelon (ORCID: https://orcid.org/0009-0007-7625-0048)
Institutions
- Université Paris-Saclay (FR)
- Erasmus Hospital (BE)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hôpital Marie Lannelongue (FR)
- German Centre for Cardiovascular Research (DE)
- Laboratoire de Recherche Vasculaire Translationnelle (FR)
- Deutsches Herzzentrum München (DE)
- Hôpital Civil, Strasbourg (FR)
- Université de Strasbourg (FR)
Publication Details
- Journal
- Circulation Heart Failure
- Published
- 2025-12-05
- DOI
- https://doi.org/10.1161/circheartfailure.125.013481
- Citations
- 1
- Primary Topic
- Pulmonary Hypertension Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.52